JP2004523556A5 - - Google Patents

Download PDF

Info

Publication number
JP2004523556A5
JP2004523556A5 JP2002567294A JP2002567294A JP2004523556A5 JP 2004523556 A5 JP2004523556 A5 JP 2004523556A5 JP 2002567294 A JP2002567294 A JP 2002567294A JP 2002567294 A JP2002567294 A JP 2002567294A JP 2004523556 A5 JP2004523556 A5 JP 2004523556A5
Authority
JP
Japan
Prior art keywords
formula
group
composition
phenyl
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002567294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004523556A (ja
JP4276841B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/006119 external-priority patent/WO2002067927A1/en
Publication of JP2004523556A publication Critical patent/JP2004523556A/ja
Publication of JP2004523556A5 publication Critical patent/JP2004523556A5/ja
Application granted granted Critical
Publication of JP4276841B2 publication Critical patent/JP4276841B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002567294A 2001-02-27 2002-02-21 精神病性障害の予防もしくは治療における使用のためのカルバメート化合物 Expired - Lifetime JP4276841B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27188901P 2001-02-27 2001-02-27
PCT/US2002/006119 WO2002067927A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating psychotic disorders
US10/081,761 US6541513B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating psychotic disorders

Publications (3)

Publication Number Publication Date
JP2004523556A JP2004523556A (ja) 2004-08-05
JP2004523556A5 true JP2004523556A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4276841B2 JP4276841B2 (ja) 2009-06-10

Family

ID=26765939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567294A Expired - Lifetime JP4276841B2 (ja) 2001-02-27 2002-02-21 精神病性障害の予防もしくは治療における使用のためのカルバメート化合物

Country Status (25)

Country Link
US (1) US6541513B2 (cg-RX-API-DMAC7.html)
EP (1) EP1401424B1 (cg-RX-API-DMAC7.html)
JP (1) JP4276841B2 (cg-RX-API-DMAC7.html)
KR (1) KR100886578B1 (cg-RX-API-DMAC7.html)
CN (1) CN1262271C (cg-RX-API-DMAC7.html)
AR (1) AR032876A1 (cg-RX-API-DMAC7.html)
AT (1) ATE346597T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002242296B2 (cg-RX-API-DMAC7.html)
BR (1) BR0207829A (cg-RX-API-DMAC7.html)
CA (1) CA2439480C (cg-RX-API-DMAC7.html)
CZ (1) CZ302412B6 (cg-RX-API-DMAC7.html)
DE (1) DE60216457T2 (cg-RX-API-DMAC7.html)
DK (1) DK1401424T3 (cg-RX-API-DMAC7.html)
ES (1) ES2275844T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0303342A3 (cg-RX-API-DMAC7.html)
IL (2) IL157588A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007722A (cg-RX-API-DMAC7.html)
NO (1) NO20033801L (cg-RX-API-DMAC7.html)
NZ (1) NZ527991A (cg-RX-API-DMAC7.html)
PL (1) PL365021A1 (cg-RX-API-DMAC7.html)
PT (1) PT1401424E (cg-RX-API-DMAC7.html)
RS (1) RS51056B (cg-RX-API-DMAC7.html)
RU (1) RU2302240C2 (cg-RX-API-DMAC7.html)
TW (1) TWI251486B (cg-RX-API-DMAC7.html)
WO (1) WO2002067927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365701A1 (en) * 2000-07-21 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
WO2003007934A1 (en) 2001-07-16 2003-01-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MXPA03007720A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad.
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP1928451B1 (en) * 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
CN101568362A (zh) * 2006-10-30 2009-10-28 詹森药业有限公司 治疗抑郁症的方法
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JP6062077B2 (ja) 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物{phenylcarbamatecompoundsforuseinpreventingortreatingpediatricepilesyandepilesy−relatedsyndromes}
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US278380A (en) * 1883-05-29 Thermometer
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
EP0480939B1 (en) * 1989-06-09 1995-01-25 The Upjohn Company Heterocyclic amines having central nervous system activity
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Similar Documents

Publication Publication Date Title
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
JP2004527492A5 (cg-RX-API-DMAC7.html)
IL189003A0 (en) Methods for treating substance-related disorders
JP2007505877A5 (cg-RX-API-DMAC7.html)
JP2004517087A5 (cg-RX-API-DMAC7.html)
TW200508180A (en) Therapeutic agents
JP2011504903A5 (cg-RX-API-DMAC7.html)
JP2004525905A5 (cg-RX-API-DMAC7.html)
RU2010148762A (ru) Тетразольные соединения для снижения концентрации мочевой кислоты
JP2004533415A5 (cg-RX-API-DMAC7.html)
RU2003128984A (ru) Производные карбаматов для использования для лечения боли
MY157373A (en) Carbamate compounds for use in preventing or treating movement disorders
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
IL157589A (en) Carbamate compounds for use in preventing or treating bipolar disorder
EA200700642A1 (ru) Способы лечения эпилептогенеза и эпилепсии
IL157590A0 (en) Carbamate compounds for use in preventing or treating bipolar disorder
CA2439480A1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
NO20072444L (no) Karbamatforbindelser for anvendelse i behandling av neurodegenerative forstyrrelser
WO2016077541A1 (en) Novel anti-infective compounds and methods using same
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
JP2004517947A5 (cg-RX-API-DMAC7.html)
MX2007010787A (es) Derivados de 1,2,4-triazinas, su preparacion y su aplicacion en terapia humana.
JP2007507467A5 (cg-RX-API-DMAC7.html)
SE0400441D0 (sv) Novel Benzofurans and Indols
IL159847A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain